Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima, Manish A. Shah, Kei Muro, Éric François, Antoine Adenis, Chih‐Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung‐Bae Kim, Se‐Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter C. Enzinger, Shukui Qin, P. Ferreira, Jia Chen, Gustavo Girotto, Christelle de la Fouchardière, Hélène Senellart, Raed Moh’d Taiseer Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, Soonmo Peter Kang, Jean‐Philippe Metges, on behalf of the KEYNOTE-181 Investigators

Journal of Clinical Oncology, 2020

National Cancer Center Hospital East, Cornell University, Aichi Cancer Center, Centre Antoine Lacassagne, Inserm, Université de Montpellier, National Taiwan University Hospital, University of Tsukuba Hospital, Asan Medical Center, Samsung Medical Center, Institut de Cancérologie de l'Ouest, Tokyo National Hospital, Peking University, Peking University Cancer Hospital, Harvard University, Dana-Farber Cancer Institute, 81th Hospital of PLA, IPO Porto, Jiangsu Cancer Hospital, Hospital de Base, Centre Léon Bérard, Institut Génétique Nantes Atlantique, The University of Kansas Cancer Center, University Cancer Center Hamburg, Merck & Co., Inc., Rahway, NJ, USA (United States), Centre Hospitalier Régional Universitaire de Brest

Publisher Website

Abstract

This research paper explore the methodology and findings associated with Journal of Clinical Oncology. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

1155

Citations

View on Google Scholar

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back